Preoperative Anti-PD-1 Antibody Plus Drug-eluting Bead TACE for BCLC Stage A/B Hepatocellular Carcinoma Beyond the Milan Criteria: A Phase II Trial
Latest Information Update: 07 Jun 2024
At a glance
- Drugs Sintilimab (Primary) ; Programmed cell death 1 receptor antagonists
- Indications Liver cancer
- Focus Therapeutic Use
Most Recent Events
- 06 Jun 2022 Planned End Date changed from 30 May 2022 to 30 Dec 2022.
- 06 Jun 2022 Planned primary completion date changed from 30 Nov 2020 to 30 Jul 2022.
- 06 Jun 2022 Status changed from recruiting to active, no longer recruiting.